Intravitreal Ranibizumab and Dexamethasone Implant Injections as Primary Treatment of Diabetic Macular Edema: The Month 24 Results from Simultaneously Double Protocol

医学 血管抑制剂 眼科 视力 糖尿病性视网膜病变 临床终点 糖尿病性黄斑水肿 地塞米松 黄斑水肿 外部限制膜 随机对照试验 外科 视网膜 糖尿病 贝伐单抗 内科学 视网膜色素上皮 化疗 内分泌学
作者
Mahmut Kaya,Ferdane Ataş,Nilüfer Koçak,Taylan Öztürk,Ziya Ayhan,Süleyman Kaynak
出处
期刊:Current Eye Research [Taylor & Francis]
卷期号:48 (5): 498-505 被引量:9
标识
DOI:10.1080/02713683.2023.2168013
摘要

Purpose To compare efficacy of simultaneously administered intravitreal dexamethasone implant (DEX implant) and ranibizumab (simultaneous double protocol) injections with ranibizumab monotherapy for diabetic macular edema (DME) at month 24.Methods This is a prospective, consecutive, clinical interventional study. Naïve eyes with DME were randomized into two groups: 34 eyes received simultaneous double-protocol therapy and 34 eyes received ranibizumab monotherapy. The primary efficacy endpoint was change in visual acuity in month 24. The secondary efficacy endpoints were to evaluate gain of ≥15 letters, morphological changes and central foveal thickness. Decreased vision from DME (study eye BCVA, 20/40 or worse Snellen equivalent using ETDRS testing), the presence of DME with ≥300 μm foveal intraretinal cystoid spaces (within 1000 μm of the centre of the fovea), subfoveal neuroretinal detachment (SND), intraretinal hyperreflective foci (HRF, within 500 μm of the centre of the fovea) or foveal lipid exudates and external limiting membrane (ELM) and ellipsoid zone (EZ) disruption (within 500 μm of the centre of the fovea) on SD-OCT were eligible to enrol.Results The mean baseline BCVA was 48 ± 23 letters in double protocol group and 52 ± 14 letters ranibizumab monotherapy group (p = 0.416). The mean number of ETDRS letters changed from baseline at 12 months versus change from baseline at month 24 in double protocol group and ranibizumab monotherapy group were +21.6 versus +20.2 and +9.6 versus +9.1, respectively. At the month 24 time point, 65.4% of patients in double protocol group and 26.2% of patients in ranibizumab monotherapy group had gained ≥15 ETDRS letters in BCVA from baseline (p < 0.001). The external limiting membrane (ELM) and ellipsoid zone (EZ) integrity were better in the double protocol group in comparison to ranibizumab monotherapy group at month 24. In addition, there was no statistically significant increase in the proportion of patients with epiretinal membrane in double protocol group at month 24, by the contrast with ranibizumab monotherapy group (p = 0.06 and p = 0.04 in the double protocol and ranibizumab monotherapy groups, respectively). From baseline to month 24, the mean central foveal thickness (CFT) was 672 ± 293 μm reduced to 278 ± 84 μm in double protocol group and was 631 ± 279 μm reduced to 356 ± 108 μm in ranibizumab monotherapy group (p < 0.001 and p < 0.001). From baseline to month 24, 38% (13/34) of eyes in double protocol group and 18% (6/34) of eyes in ranibizumab monotherapy group had at least 5 mmHg of IOP elevation (p = 0.012). Two grades or more increased cataract density were detected 27% (6/22) of eyes in the double protocol group and in 12.5% (3/24) of eyes in the ranibizumab monotherapy group from baseline to month 24 (p = 0.032).Conclusion According to the improvements in visual acuity and morphological changes achieved at month 24, the simultaneous double protocol therapy can be an effective treatment option for DME with inflammatory biomarkers on OCT or/and decreased visual acuity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
勤劳的唇膏完成签到,获得积分10
4秒前
taowenquan完成签到 ,获得积分10
11秒前
旅行者N0501完成签到,获得积分10
13秒前
灵巧的长颈鹿完成签到,获得积分10
19秒前
怼怼完成签到 ,获得积分10
21秒前
nikki完成签到 ,获得积分10
21秒前
马伯乐完成签到 ,获得积分10
22秒前
Hello的应助被豆豆采纳,获得10
22秒前
26秒前
动人的冷霜完成签到,获得积分10
27秒前
迅速的新竹完成签到,获得积分10
27秒前
Peiqi的应助被雪山飞龙采纳,获得10
30秒前
32秒前
蓝精灵完成签到,获得积分10
34秒前
yuki完成签到 ,获得积分10
34秒前
漾漾的羊完成签到 ,获得积分10
36秒前
dianeil完成签到,获得积分10
44秒前
王不凡完成签到 ,获得积分10
46秒前
LWJ完成签到 ,获得积分10
46秒前
竹舍翁暮雨君完成签到 ,获得积分10
49秒前
机智的孤兰完成签到 ,获得积分10
49秒前
拼搏忆文完成签到,获得积分10
52秒前
康康舞曲完成签到 ,获得积分10
53秒前
XU博士完成签到,获得积分10
54秒前
轻歌水越完成签到 ,获得积分10
55秒前
风趣朝雪完成签到,获得积分10
56秒前
Robin完成签到 ,获得积分10
59秒前
一瓣橘子完成签到,获得积分10
1分钟前
kk完成签到,获得积分10
1分钟前
Fan完成签到 ,获得积分0
1分钟前
蔡勇强完成签到 ,获得积分10
1分钟前
bo完成签到 ,获得积分0
1分钟前
lpp完成签到 ,获得积分10
1分钟前
Heby完成签到 ,获得积分10
1分钟前
小山己几完成签到,获得积分10
1分钟前
吉吉完成签到,获得积分10
1分钟前
望向天空的鱼完成签到 ,获得积分10
1分钟前
詹姆斯哈登完成签到,获得积分0
1分钟前
高贵的鸿涛完成签到,获得积分10
1分钟前
凡凡完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180053
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808682
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012